Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar 18:13:777-784.
doi: 10.2147/DMSO.S238588. eCollection 2020.

Alterations in the Levels of Circulating and Endothelial Progenitor Cells Levels in Young Adults with Type 1 Diabetes: A 2-Year Follow-Up from the Observational METRO Study

Miriam Longo  1   2 , Lorenzo Scappaticcio  1 , Giuseppe Bellastella  1   2 , Vlenia Pernice  1 , Paolo Cirillo  1 , Antonietta Maio  1 , Filomena Castaldo  1   2 , Dario Giugliano  1   2 , Katherine Esposito  1   3 , Maria Ida Maiorino  1   2 ; METRO Study Group
Affiliations

Alterations in the Levels of Circulating and Endothelial Progenitor Cells Levels in Young Adults with Type 1 Diabetes: A 2-Year Follow-Up from the Observational METRO Study

Miriam Longo et al. Diabetes Metab Syndr Obes. .

Abstract

Purpose: Type 1 diabetes is associated with high risk of cardiovascular disease (CVD). Reduced levels of circulating progenitor cells (CPCs) and endothelial progenitor cells (EPCs) have been indicated as a risk factor for adverse cardiovascular outcomes and death in people at high cardiovascular risk. The aim of the present study was to evaluate the change in CPCs and EPCs levels in a population of young type 1 diabetic patients treated with intensive insulin regimen over a period of 2 years.

Patients and methods: A total of 204 type 1 diabetic patients, of whom 84 treated with insulin pump (CSII) and 120 with multiple daily insulin injections (MDI), completed a 2-year follow-up. Clinical measurements, including the indices of glycemic control and glucose variability, were collected at baseline and after 2 years. Both CPC and EPC cell count were assessed by flow cytometry.

Results: Mean age of participants was 24.5 years and mean diabetes duration was 13.6 years. After 2 years, we found a significant reduction of HbA1c (-0.3% versus baseline, P <0.001), associated with decrease in mean amplitude of glucose excursion (MAGE) (-0.5 mmol/L versus baseline, P<0.001), continuous overall net glycemic action (CONGA) (-0.2 mmol/L versus baseline, P=0.006), and blood glucose standard deviation (BGSD) (-0.2 mmol/L versus baseline, P<0.001). The number of all EPCs phenotypes, but not CPC cell count, significantly raised up in the entire population, with higher increase in CSII group. MAGE resulted as an independent predictor for increased levels of both CD34+ (P = 0.020) and CD34+KDR+ (P = 0.004) cell count in the whole population.

Conclusion: Over a 2-year follow-up, young type 1 diabetic patients showed an increase in circulating EPCs levels, which was higher in patients with CSII. Glucose variability resulted as an independent predictor of the raised levels of EPCs in this selected population.

Keywords: CSII; MDI; circulating progenitor cells; endothelial progenitor cells; glucose variability; type 1 diabetes.

PubMed Disclaimer

Conflict of interest statement

The abstract of this paper was presented at the 54th EASD Annual Meeting of the European Association for the Study of Diabetes as a poster presentation with interim findings. The poster’s abstract was published in Diabetologia (2018) 61 (Suppl 1): 1. https://doi.org/10.1007/s00125-018-4693-0. Miriam Longo and Lorenzo Scappaticcio shared the first authorship. DG has held lectures for Novo Nordisk, AstraZeneca, Lilly, Mundipharma, Sanofi. KE has held lectures for Novo Nordisk, Lilly, AstraZeneca, Bruno, Mundipharma, Boehringer Ingelheim, Roche, Lifescan, Abbott. MIM has held lectures for Roche, Lifescan and Abbott. All the other authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Change of circulating levels of six phenotypes of EPCs in the overall population over two year-follow-up.
See this image and copyright information in PMC

References

    1. Livingstone SJ, Levin D, Looker HC, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008–2010. JAMA. 2015;313(1):37–44. doi:10.1001/jama.2014.16425 - DOI - PMC - PubMed
    1. Huo L, Shaw JE, Wong E, Harding JL, Peeters A, Magliano DJ. Burden of diabetes in Australia: life expectancy and disability-free life expectancy in adults with diabetes. Diabetologia. 2016;59(7):1437–1445. doi:10.1007/s00125-016-3948-x - DOI - PubMed
    1. Maahs DM, Daniels SR, de Ferranti SD, et al. Cardiovascular disease risk factors in youth with diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2014;130(17):1532–1558. doi:10.1161/CIR.0000000000000094 - DOI - PubMed
    1. Gorst C, Kwok CS, Aslam S, et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38(12):2354–2369. doi:10.2337/dc15-1188 - DOI - PubMed
    1. Saad MI, Abdelkhalek TM, Saleh MM, et al. Insights into the molecular mechanisms of diabetes-induced endothelial dysfunction: focus on oxidative stress and endothelial progenitor cells. Endocrine. 2015;50(3):537–567. - PubMed